Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases

Molecular and Cellular Endocrinology

Volumn 248, Issue 1-2, 2006, Pages 218-224

  Deluca, Dominga ^a   Möller, Gabriele ^a   Rosinus, Andrea ^a   Elger, Walter ^b,c   Hillisch, Alexander ^b,d   Adamski, Jerzy ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b EnTec GmbH   (Germany)

^c Bayer HealthCareAG ^*  (Germany)

^d BAYER AG   (Germany)

Author keywords

17Beta hydroxysteroid dehydrogenase; Fluorine substitution; Inhibitor

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR; 17BETA HYDROXYSTEROID DEHYDROGENASES TYPE 1; 17BETA HYDROXYSTEROID DEHYDROGENASES TYPE 2; 17BETA HYDROXYSTEROID DEHYDROGENASES TYPE 4; 17BETA HYDROXYSTEROID DEHYDROGENASES TYPE 5; 17BETA HYDROXYSTEROID DEHYDROGENASES TYPE 7; ENZYME INHIBITOR; ESTROGEN DERIVATIVE; FLUORINE DERIVATIVE; J 1306; J 1309; J 2141; J 2180; J 2185; J 2186; J 2403; J 2404; J 2406; J 2594; J 2682; J 2721; J 2793; J 2819; J 3062; J 3079; J 3345; RECOMBINANT ENZYME; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG BINDING; DRUG EFFECT; ENZYME INHIBITION; IN VITRO STUDY; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

17-HYDROXYSTEROID DEHYDROGENASES; ENZYME INHIBITORS; ESTRENES; ESTROGENS; FLUORINE; HUMANS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33644923476     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2005.11.037     Document Type: Conference Paper

References (29)

1. J. Adams, M. Garcia, and H. Rochefort Estrogenic effects of physiological concentrations of 5-androstene-3beta, 17beta-diol and its metabolism in MCF7 human breast cancer cells Cancer Res. 41 1981 4720 4726
2. S. Andersson, and N. Moghrabi Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases Steroids 62 1997 143 147
3. R. Breton, D. Housset, C. Mazza, and J.C. Fontecilla-Camps The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors Structure 4 8 1996 905 915
4. D. Deluca, A. Fritz, R. Mindnich, G. Möller, and J. Adamski Biochemical genetics of 17beta-hydroxysteroid dehydrogenases Curr. Top. Steroid Res. 4 2004 227 242
5. L.L. Engel, and E.V. Groman Human placental 17beta-estradiol dehydrogenase: characterization and structural studies Recent Prog. Horm. Res. 30 1974 139 169
6. N. Fournet-Dulguerov, N.J. MacLusky, C.Z. Leranth, R. Todd, C.R. Mendelson, E.R. Simpson, and F. Naftolin Immunohistochemical localization of aromatase cytochrome P-450 and estradiol dehydrogenase in the syncytiothrophoblast of the human placenta J. Clin. Endocrinol. Metab. 65 1987 757 764
7. S.A. Ghersevich, M.H. Poutanen, H.K. Martikainen, and R. Vihko Expression of 17β-hydroxysteroid dehydrogenase type 1 in human granulosa cells: correlation with follicular size, cytochrome P450 aromatase activity and oestradiol production J. Endocrinol. 143 1994 139 150
8. F. Labrie, V. Luu-The, S. Lin, J. Simard, and C. Labrie Role of 17beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues Trends Endocrinol. Metab. 11 2000 421 427
9. F. Leenders, J.G. Tesdorpf, M. Markus, T. Engel, U. Seedorf, and J. Adamski Porcine 80-kDa protein reveals intrinsic 17 beta-hydroxysteroid dehydrogenase, fatty acyl-CoA-hydratase/dehydrogenase, and sterol transfer activities J. Biol. Chem. 271 10 1996 5438 5442
10. A. Liu, K.E. Carlson, and J.A. Katzenellenbogen Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography J. Med. Chem. 35 1996 2113 2129
11. R. Mindnich, G. Möller, and J. Adamski The role of 17beta-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 218 2004 7 20
12. S. Nobel, L. Abrahmsen, and U. Oppermann Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones Eur. J. Biochem. 268 2001 4113 4125
13. U. Oppermann, S. Salim, M. Hult, G. Eissner, and H. Jornvall Regulatory factors and motifs in SDR enzymes Adv. Exp. Med. Biol. 463 1999 365 371
14. H. Peltoketo, V. Luu-The, J. Simard, and J. Adamski 17Beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes J. Mol. Endocrinol. 23 1999 1 11
15. T.M. Penning Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action Hum. Reprod. Update 9 2003 193 205
16. D. Poirier Inhibitors of 17β-hydroxysteroid dehydrogenases Curr. Med. Chem. 10 2003 453 477
17. M. Poutanen, V. Isomaa, H. Peltoketo, and R. Vihko Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis J. Steroid. Biochem. Mol. Biol. 55 1995 525 532
18. W. Qiu, R.L. Campbell, A. Gangloff, P. Dupuis, R.P. Boivin, M.R. Tremblay, D. Poirier, and S.-X. Lin A concerted, rational design of type 1 17β-hydroxysteroid dehydrogenase inhibitors:estradiol-adenosine hybrids with high affinity FASEB J. 16 2002 1829 1831
19. M. Rarey, B. Kramer, T. Lengauer, and G. Klebe A fast flexible docking method using an incremental construction algorithm J. Mol. Biol. 261 1996 470 489
20. K.J. Ryan, and L.L. Engel The interconversion of estrone and estradiol by human tissue slices Endocrinology 52 1953 287 291
21. K.M. Sam, R.P. Boivin, M.R. Tremblay, S. Auger, and D. Poirier C16 and C17 derivatives of estradiol as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships Drug Des. Discov. 15 1997 157 180
22. H. Sasano, A.R. Frost, R. Saitoh, N. Harada, M. Poutanen, R. Vihko, S.E. Bulun, S.G. Silverberg, and H. Nagura Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma J. Clin. Endocrinol. Metab. 81 1996 4042 4046
23. C. Sawetawan, L. Milevich, A. Word, B.C. Carr, and W.E. Rainey Compartimentalization of type I 17β-hydroxysteroid oxidoreductase in the human ovary Mol. Cell. Endocrinol. 99 1994 161 168
24. D.B. Thomas Do hormones cause breast cancer? Cancer 53 1987 595 604
25. M.R. Tremblay, and D. Poirier Overview of a rational approach to design type I 17β-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation J. Steroid Biochem. Mol. Biol. 66 1998 179 191
26. Tripos Inc., SYBYL, 2000. 1699 S. Hanley Road, Suite 303, St. Louis, MO, July 6.
27. P. Vihko, P. Härkönen, O. Oduwole, S. Törn, R. Kurkela, K. Porvari, A. Pulkka, and V. Isomaa 17β-Hydroxysteroid dehydrogenases and cancers J. Steroid Biochem. Mol. Biol. 83 2003 119 122
28. P. Vihko, P. Härkönen, P. Soronen, S. Törn, A. Herrala, R. Kurkela, A. Pulkka, O. Oduwole, and V. Isomaa 17β-Hydroxysteroid dehydrogenases - their role in pathophysiology Mol. Cell. Endocrinol. 215 2004 83 88
29. R. Vihko, and D. Apter Endogenous steroids in the pathophysiology of breast cancer Crit. Rev. Oncol. Hematol. 9 1989 1 16